THE WOODLANDS, Texas -- (BUSINESS WIRE) -- MolecularHealth announced a unique agreement today with GATC Biotech, a global leading DNA sequencing service provider. GATC Biotech will provide protocols, support and extensive training of MolecularHealth’s laboratory staff. Additionally, MolecularHealth will use GATC Biotech’s LIMS (Laboratory Information Management System) in its newly opened clinical lab. These contributions will complement MolecularHealth’s next generation sequencing offerings and its proprietary TreatmentMAP™ oncology treatment decision support platform.
“In preparation for the launch of TreatmentMAP in Q1 of this year, it’s essential that we put the best protocols in place for our lab,” said Lloyd Everson, M.D., CEO of MolecularHealth. “GATC Biotech has decades of experience in sequencing technology and services, and a standardized, validated, automated process. Their proven expertise will be invaluable to our team, as we work to provide personalized, actionable information to cancer patients and their medical teams.”
“GATC Biotech is a global leader in genomic sequencing and we are pleased to partner with MolecularHealth on this strategic collaboration to improve life for cancer patients,” said Peter Pohl, CEO of GATC Biotech. “We are convinced that our know-how, combined with MolecularHealth’s data interpretation, will pave the way for personalized medicine by enabling substantiated decisions about individual cancer care,” he adds.
MolecularHealth’s lab, located in Houston metro area, will offer two laboratory-developed tests: a targeted gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome. The company, backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments.
MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. MolecularHealth’s team of doctors, scientists, IT and business experts—including founders and executives of LION Bioscience, US Oncology and Novartis—works in partnership with some of the world’s leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has locations in The Woodlands, Texas, Boston, Mass. and Heidelberg, Germany. Visit www.molecularhealth.com for more information and follow us on Twitter at www.twitter.com/molecularhealth.
ABOUT GATC BIOTECH
GATC Biotech, a family-owned business, is Europe’s leading service provider of DNA and RNA sequencing. For over two decades, the company has offered sequencing and bioinformatics solutions from single samples up to large scale projects. During this time, GATC Biotech has sequenced more than six million samples, ten thousands of bacterial, plant and other whole genomes, as well as hundreds of whole human genomes. The company offers true multiplatform sequencing using all leading sequencing technologies in its own labs. Its headquarter in Constance, Germany houses its ISO 17025 certified Genome and Diagnostic Centre with focus on next and third generation sequencing. The European Custom Sequencing Centre located in Cologne, Germany focuses on Sanger sequencing and serves as the logistical hub within Europe. All laboratories have highly integrated and fully automated processing pipelines, ensuring full compliance with latest state-of-the-art quality standards. For more information please visit www.gatc-biotech.com.